Fig. 1.

Chronological changes of the patient’s liver function tests. The first nivolumab dose was administered on day 1. The patient’s serum AST, ALT, g-GTP, and ALP levels did not decrease appreciably after the amount of prednisolone was increased. We then initiated administration of UDCA 600 mg/day and bezafibrate 400 mg/day. After the start of UDCA and bezafibrate administration, the serum levels of AST, ALT, g-GTP, and ALP decreased, even with a restart of prednisolone tapering. ALP Alkaline phosphatase, ALT Alanine aminotransferase, AST Aspartate aminotransferase, g-GTP Gamma-glutamyl transpeptidase, UDCA Ursodeoxycholic acid